News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI
Dana-Farber Cancer Institute/dana-farber.org
Nov 26, 2024, 17:58

Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI

Dana-Farber’s Breast Oncology Center shared a post on X:

“We are leading a phase 2 study, called TRUDI, to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn if the intervention works in stage III, HER2-expressing Inflammatory Breast Cancer.”

Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI

Read further.

More featuring Dana-Farber’s Breast Oncology Center.

cancer Dana-Farber’s Breast Oncology Center Durvalumab inflammatory breast cancer OncoDaily Oncology Trastuzumab deruxtecan TRUDI
Special Coverage
Celebrities
Feb 22, 2025, 11:40
Remembering Saxophonist James Casey: His Battle with Colon Cancer and Advocacy
Career
Feb 22, 2025, 11:36
Joseph H. Antin Received ASTCT Lifetime Achievement Award at 2025 Tandem Meetings
Science
Feb 22, 2025, 11:28
Myeloma Paper of the Day, February 22nd, suggested by Robert Orlowski
Blog
Feb 22, 2025, 11:22
Yan Leyfman: Great experience speaking at the NSHSS Pre-Medicine Workshop
Insight
Feb 22, 2025, 11:15
Henrik Ullum: The urgent need to protect WHO is also an opportunity
Oncolibrary
Feb 22, 2025, 11:02
New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Blog
Feb 22, 2025, 10:57
Tsetsegsaikhan Batmunkh: Factsheets for parents on childhood cancers and essential medicines in the Mongolian
Blog
Feb 22, 2025, 10:47
Akhilesh Bind: Advancing political leadership for equitable cancer care
Blog
Feb 22, 2025, 10:41
Nominations close for the 2025 Szent-Györgyi Prize for Progress in Cancer Research - NFCR
Blog
Feb 22, 2025, 06:28
Michael Sapienza: Breaking the stigma associated with CRC screening with Lead From Behind
Blog
Feb 22, 2025, 05:23
Sanam Loghavi: Excited to see the draft agenda for the inaugural Women in Hematology meeting
Blog
Feb 22, 2025, 05:18
Francisco J. Esteva: The clinical applications of PARPi across various cancers